Pipeline

Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
COVID-19 Programs  

COVISTIX™ (diagnostic) Rapid Antigen Test

0%*

Emergency Use Authorization (EUA) in Mexico (COFEPRIS), Brazil (ANVISA), and CE Marked in Europe

COVI-DROPS™ (treatment) Neutralizing Antibody (Intranasal) in Outpatients

60.2%*

COVI-AMG™ (treatment) Neutralizing Antibody (IV) in Outpatients

60.2%*

COVI-SHIELD™ (treatment) Neutralizing Antibody (IV and IN) in Outpatients and Inpatients

20%*

ABIVERTINIB (treatment) Severe COVID-19 in ICU Patients

82%*

Pivotal Trial Pending FDA Clearance

COVI-MSC (treatment) ARDS due to COVID-19 in ICU Patients

82%*

Pivotal Trial in Brazil

Mpro Inhibitor (oral pill) Anti-viral

20%*

Omicron mRNA Vaccine Vaccine

20%*

Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
Immunotherapy  

Abivertinib NSCLC

82%*

Abivertinib B Cell Lymphomas

60.2%*

Abivertinib Prostate

20%*

Abivertinib Lupus

20%*

Abivertinib MS

20%*

Abivertinib GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*In Partnership with Lee’s Pharm in China

PD-L1 (STI-3031)** Cervical Cancer

82%*

**In US and in partnership with ImmuneOncia in Korea

CD47 Solid Tumors

40%*

CD38 DAR-T Multiple Myeloma

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, and esophageal

40%*

TROP2 ADC* Solid Tumors

40%*

* In China

Seprehvec™ oncolytic virus Solid Tumors; CNS Tumors

40%*

BCMA ADC Liquid Tumors

20%*

Bevacizumab-ADNAB™ Endometrial Cancer

40%*

In partnership with Mayo Clinic

Bevacizumab-ADNAB™ Ovarian Cancer

40%*

In partnership with Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

In partnership with Mayo Clinic
Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
Pain  

ZTlido™ 1.8%
Postherpetic Neuralgia - PHN

99.8%*

SP-102
Lumbar Radicular/Sciatica Pain

82%*

SP-103
Acute Back Pain

40%*

SP-104
Fibromyalgia

20%*

RTX (resiniferatoxin)
Epidural injection
Intractable Pain in Advanced Cancer

60.3%*

Orphan designation

RTX (resiniferatoxin)
Intra-articular route
Moderate to Severe Knee OA Pain

60.2%*

Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
Lymphatic Delivery  

Sofusa® anti-TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL)

40%*

Sofusa® anti-PD-1 Melanoma

40%*

In partnership with Mayo Clinic
COVID-19 Programs
Key Programs (Indication) Phase
COVISTIX™ (diagnostic) FDA EUA
COVIDROPS™ (treatment) Ph II
COVI-AMG™ (treatment) Ph II
COVISHIELD™ (treatment) Preclinical
ABIVERTINIB (treatment) Ph III
COVI-MSC (treatment) Ph III
Mpro Inhibitor (oral pill) (anti-viral) Preclinical
Omicron mRNA Vaccine (vaccine) Preclinical
Immunotherapy
Key Programs (Indication) Phase
Abivertinib (NSCLC) Ph III
Abivertinib (B Cell Lymphomas) Ph II
Abivertinib (Prostate) Preclinical
Abivertinib (Lupus) Preclinical
Abivertinib (MS) Preclinical
Abivertinib (GvHD) Preclinical
PD-L1 (Socazolimab)*(SCLC) Ph III
PD-L1 (STI-3031)** (Cervical Cancer) Ph III
CD47 (Solid Tumors) Ph I
CD38 CAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, and esophageal) Ph I
TROP2 ADC* (Solid Tumors) Ph I
Seprehvec™ oncolytic virus (Solid Tumors; CNS Tumors) PH I
BCMA ADC (Liquid Tumors) Preclinical
Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I
Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Pain
Key Programs (Indication) Phase
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
SP-102 (Lumbar Radicular/Sciatica Pain) Ph III
SP-103 (Acute Back Pain) Ph I
SP-104 (Fibromyalgia) Preclinical
RTX (resiniferatoxin) Epidural injection (Intractable Pain in Advanced Cancer) Ph II
RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA Knee Pain) Ph II
Lymphatic Delivery
Key Programs (Indication) Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I
Sofusa® anti-PD-1 (Melanoma) Ph I